Cephalon, Inc. v. Watson Pharmaceuticals, Inc.
769 F. Supp. 2d 729
D. Del.2011Background
- Plaintiffs Cephalon, Inc. and CIMA Labs, Inc. own Khankari patents ('604, '590) and Cephalon owns the '981 patent; these relate to oral transmucosal drug delivery and were listed in the Orange Book for Cephalon's fentanyl buccal NDA.
- Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc. filed an ANDA for a generic fentanyl buccal tablet in 2008, prompting patent infringement litigation.
- Two related actions (infringement and declaratory judgment about the '981 patent) were consolidated for discovery and tried in a bench trial from May 10–17, 2010.
- The court construed the Khankari claim language, addressed validity under 35 U.S.C. § 112, and evaluated infringement and validity post-trial.
- The court concluded Cephalon failed to prove infringement by a preponderance of the evidence and held the Khankari claims invalid for lack of enablement; the court did not find Hesnard anticipatory or Stanley/Eichman-based obviousness supporting invalidity.
- The court ordered judgment for defendants on infringement and for plaintiffs on validity, with the overall decision that the asserted claims are invalid for lack of enablement.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Construction of ‘at least one effervescent agent’ | Cephalon argues includes an effervescent agent that evolves gas; breadth includes single or multiple components. | Watson contends it requires an effervescent couple (two components) | Broad enough to include at least one gas-evolving compound. |
| Sufficiency of the amount to increase absorption | Argues the amount is sufficient to increase absorption across the oral mucosa. | Argues the amount must exceed that for disintegration and not count pH-adjusting substances. | Amount must be greater than disintegration and distinct from pH-adjusting substance. |
| Infringement proof | Cephalon must show Watson’s ANDA product meets all claim limitations or equivalents. | Watson’s product allegedly does not meet the effervescent-reaction limitation. | Cephalon did not prove infringement by a preponderance; no sufficient showing of gas-evolution increasing absorption. |
| Enablement under 35 U.S.C. § 112 | Claims enabled by disclosure of a single-compound effervescent with possible co-administration. | Enablement lacking for single-compound effervescent; need for co-administration details. | Khankari claims invalid for lack of enablement as construed (single compound suffices not disclosed). |
| Anticipation/Obviousness | Hesnard anticipates; Stanley/Eichman combination shows obviousness. | Hesnard not anticipatory; no adequate teaching of single-compound effervescent; obviousness not proven. | No anticipation; no clear and convincing evidence of obviousness. |
Key Cases Cited
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (intrinsic evidence governs claim construction; ordinary meaning in context of the specification)
- Markman v. Westview Instruments, Inc., 517 U.S. 370 (U.S. 1996) (lawful claim construction; reads claims from the perspective of a skilled artisan)
- Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576 (Fed. Cir. 1996) (claims must be interpreted in view of the specification)
- Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361 (Fed. Cir. 1997) (enablement and written description require enablement of full scope)
- ALZA Corp. v. Andrx Pharmaceuticals, LLC, 603 F.3d 935 (Fed. Cir. 2010) (enablement and the burden of proving invalidity)
- Abbott Labs. v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009) (bioequivalence not dispositive of infringement by equivalents)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (U.S. 2007) (requires reasoned, common-sense approach to obviousness)